Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

31.4%

11 terminated/withdrawn out of 35 trials

Success Rate

68.6%

-17.9% vs industry average

Late-Stage Pipeline

57%

20 trials in Phase 3/4

Results Transparency

0%

0 of 24 completed trials have results

Key Signals

11 terminated

Enrollment Performance

Analytics

Phase 4
12(36.4%)
Phase 2
8(24.2%)
Phase 3
8(24.2%)
Phase 1
5(15.2%)
33Total
Phase 4(12)
Phase 2(8)
Phase 3(8)
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (35)

Showing 20 of 35 trials
NCT03956979Phase 2Completed

A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia

Role: collaborator

NCT04377945Phase 2Terminated

Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components

Role: lead

NCT06014853Phase 1Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects

Role: lead

NCT03465787Phase 3Completed

A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia

Role: lead

NCT04347915Phase 2Completed

The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19

Role: lead

NCT04891302Phase 2Completed

The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19

Role: lead

NCT02711969Phase 1Completed

A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

Role: lead

NCT00313287Phase 3Terminated

Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBV

Role: lead

NCT00313274Phase 3Terminated

Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patients With HBeAg(-) Chronic HBV

Role: lead

NCT00362505Phase 3Terminated

Safety and Antiviral Activity of Clevudine in Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials

Role: lead

NCT00362700Phase 2Terminated

Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201

Role: lead

NCT00362674Completed

Durability of Antiviral Activity in Chronic HBV Patients Who Showed Complete Response in L-FMAU-301,302 or 303 Trial

Role: lead

NCT02439203Phase 2Completed

Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia

Role: lead

NCT01264094Phase 4Terminated

A Study to Evaluate the Efficacy and the Change of sAg Levels in Chronic Hepatitis B Patients Receiving Clevudine Treatment Over the Long Period

Role: lead

NCT01624779Phase 1Completed

Intrathecal Transplantation Of Autologous Adipose Tissue Derived MSC in the Patients With Spinal Cord Injury

Role: lead

NCT01507922Phase 4Completed

Comparative Efficacy and Safety of Fenoverine

Role: lead

NCT01264354Phase 4Completed

An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B

Role: lead

NCT01266005Phase 4Terminated

A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients

Role: lead

NCT01264133Phase 4Terminated

A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B

Role: lead

NCT01263002Phase 4Completed

A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC

Role: lead